IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roudy who wrote (1647)	3/23/1999 9:40:00 PM
From: Maurice Winn	1 Recommendation Read Replies (1) of 1762

*Oncolym with Cu67 instead of I131. Also, how about IDEC buys TCLN and gets some serious lymphoma treatment happening. They have good resources to combine and the combination would save money and make it easier to use combination treatments, such as Rituxan/Oncolym/CHOP, in one patient where CD20 is present but not too strong and Oncolym would help. techstocks.com Post from Techniclone stream. That would improve IDEC product portfolio and profit prospects. The market capitalisation of TCLN is tempting. Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next